Home>Topics>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals ARNA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. The Strongest Small Caps In The Market

      Headlines

      Tue, 22 May 2012

      By Benzinga : By Scott Rubin Traders who are comfortable with a high level of risk/reward frequently will gravitate to the small-cap space where big gains (and losses) in a short amount of time are commonplace. One of the strategies that momentum-oriented small-cap traders utilize is relative ...

    2. Arena Pharmaceuticals ( ARNA ) +4.7% to $6.24 after it yesterday completed its secondary public offering and underwriters fully exercised their option to purchase additional stock. Arena sold almost ...

      Headlines

      Tue, 22 May 2012

      Arena Pharmaceuticals ( ARNA ) +4.7% to $6.24 after it yesterday completed its secondary public offering and underwriters fully exercised their option to purchase additional stock. Arena sold almost 12.65M shares at $5.50 each, raising nearly $70M. Post your comment!

    3. Today's Market News To Trade On: 5 Stocks Moving On News

      Headlines

      Tue, 22 May 2012

      By Matthew Smith : Both Asia and Europe are up strongly this morning, and this could be good for our markets although currently U.S. futures are lower. It appears that maybe we are backing off due to yesterday's big day, but if we do not have any bad news out of Europe we could once again see ...

    4. Brief Review Of A Few Biotechs

      Headlines

      Mon, 21 May 2012

      By Mina Shaker : The following is a review of three biotech stocks with potential for growth. Amarin ( AMRN ), Osiris (OSIR and Abbott ( ABT ) are three companies with either recent breakthroughs, a catalyst, or a possible place to ride out a coming storm. Amarin ( AMRN ) On Tuesday May 8th Amarin

    5. Today's Market News To Trade On: 5 Stocks Moving On News

      Headlines

      Thu, 17 May 2012

      By Matthew Smith : Markets sold off yesterday once again on news coming out of Europe. There are serious issues on the continent, and one has to ask who is in charge in Greece. We know its currently a judge, but the politicians certainly were not before, or after the elections and it is obvious ...

    6. Hitting The Jackpot With Small-Cap Bio Pharma Investment, Part 3: The Immune System

      Headlines

      Wed, 16 May 2012

      By Scott Matusow : In the final part of my three part series on "Hitting The Jackpot With Small Cap Bio Pharma Investment," I shift the focus to the what looks like the future of cancer treatment therapy. What if cancer could be arrested, forced into remission, and even cured by simply manipulating

    7. Premarket gainers: [[OSUR]] +30%. [[COGO]] +15%. [[SINA]] +12%. [[ABMD]] +9%. [[VELT]] +8%. [[FTR]] +6%. Losers: [[CLNT]] -29%. [[JCP]] -15%. [[TAXI]] -9%. [[NBG]] -8%. [[ANF]] -7%. [[ ARNA ]] -6%. ...

      Headlines

      Wed, 16 May 2012

      Premarket gainers: OSUR +30% . COGO +15% . SINA +12% . ABMD +9% . VELT +8% . FTR +6% . Losers: CLNT -29% . JCP -15% . TAXI -9% . NBG -8% . ANF -7% . ARNA -6% . WHX -5% . KERX -5% . Post your comment!

    8. 5 Biotechnology Stocks With Upcoming Catalysts

      Headlines

      Wed, 16 May 2012

      By Helix Investment Management : Of all the sectors in the stock market, no sector moves more due to corporate developments than the biotechnology sector. A single drug trial or FDA decision can send stocks soaring, or plunging. Due to this trend, many investors choose to trade biotechnology stocks

    9. Arena - What Now?

      Headlines

      Tue, 15 May 2012

      By Mina Shaker : In case you have been sleeping under a rock, Arena Pharmaceutical's ( ARNA ) weight loss drug, Lorcaserin, was approved by an advisory board on Thursday afternoon. Friday, the stock sky rocketed up

    10. Public Offerings Create Investing Opportunities In Biotech Sector

      Headlines

      Tue, 15 May 2012

      By The Swiss Trader : When investors think of a public offering they picture a private company becoming a public company or an already public company requesting more money from investors. Initial public offerings are often very attractive to private entities because of the large premiums that ...

    « Prev12345Next »
    Content Partners